Triple-negative breast carcinoma (TNBC) is one of the subtypes of breast cancer, known to have a poor prognosis.The most common risk factor is the family history of breast carcinoma, with germline mutation on BRCA1/2 genes being frequently found in comparison to other subtypes. However, non-metastatic TNBC is highly heterogeneous; two subgroups of patients can be described: on the one hand, patients with high-risk disease, not achieving pathological complete response (pCR) despite intense neoadjuvant treatment, and on the other hand, a second group of patients with good prognosis, achieving pCR with less pre-surgery treatment. There is an ongoing effort to de-escalate and escalate therapy, tailoring treatment better to the patients who need it at the right time.
AIM OF THE WORK:
This study aimed to assess the germline BRCA 1/2 mutation and PD-L1 expression in patients with non-metastatic TNBC presented at the Alexandria Clinical Oncology department. It also sought the correlation of the above biomarkerswith the clinicopathological characteristics and the response to neoadjuvant chemotherapy.